Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives

Christoph U. Correll; Koen Demyttenaere; Andrea Fagiolini; Göran Hajak; Stefano Pallanti; Giorgio Racagni; Swaran Singh

doi:10.2217/fnl-2020-0012

Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives

Christoph U. Correll, Koen Demyttenaere, Andrea Fagiolini, Göran Hajak, Stefano Pallanti, Giorgio Racagni, Swaran Singh

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

Original language	English
Article number	0012
Journal	Future Neurology
Volume	15
Issue number	4
DOIs	https://doi.org/10.2217/fnl-2020-0012
State	Published - Nov 2020
Externally published	Yes

Keywords

D3 receptor
cariprazine
dopamine
negative symptoms
partial agonist
schizophrenia

Access to Document

10.2217/fnl-2020-0012

Cite this

@article{0cca6474b1d94c31bc132fef8f1756a5,

title = "Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives",

abstract = "In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.",

keywords = "D3 receptor, cariprazine, dopamine, negative symptoms, partial agonist, schizophrenia",

author = "Correll, {Christoph U.} and Koen Demyttenaere and Andrea Fagiolini and G{\"o}ran Hajak and Stefano Pallanti and Giorgio Racagni and Swaran Singh",

year = "2020",

month = nov,

doi = "10.2217/fnl-2020-0012",

language = "English",

volume = "15",

journal = "Future Neurology",

issn = "1479-6708",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Cariprazine in the management of negative symptoms of schizophrenia

T2 - State of the art and future perspectives

AU - Correll, Christoph U.

AU - Demyttenaere, Koen

AU - Fagiolini, Andrea

AU - Hajak, Göran

AU - Pallanti, Stefano

AU - Racagni, Giorgio

AU - Singh, Swaran

PY - 2020/11

Y1 - 2020/11

N2 - In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

AB - In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

KW - D3 receptor

KW - cariprazine

KW - dopamine

KW - negative symptoms

KW - partial agonist

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85097432876&partnerID=8YFLogxK

U2 - 10.2217/fnl-2020-0012

DO - 10.2217/fnl-2020-0012

M3 - Review article

AN - SCOPUS:85097432876

SN - 1479-6708

VL - 15

JO - Future Neurology

JF - Future Neurology

IS - 4

M1 - 0012

ER -

Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives

Abstract

Keywords

Access to Document

Fingerprint

Cite this